Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $29.1 million.

  • Akebia Therapeutics' Net Cash Flow rose 63235.29% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 116092.6%. This contributed to the annual value of $9.0 million for FY2024, which is 11846.26% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Net Cash Flow of $29.1 million as of Q3 2025, which was up 63235.29% from $23.9 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Net Cash Flow registered a high of $61.5 million during Q1 2025, and its lowest value of -$57.4 million during Q4 2021.
  • In the last 5 years, Akebia Therapeutics' Net Cash Flow had a median value of -$3.6 million in 2023 and averaged -$3.3 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Net Cash Flow tumbled by 91993.09% in 2023, and later soared by 652727.27% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Net Cash Flow stood at -$57.4 million in 2021, then rose by 4.75% to -$54.7 million in 2022, then surged by 93.42% to -$3.6 million in 2023, then soared by 596.3% to $17.9 million in 2024, then skyrocketed by 63.19% to $29.1 million in 2025.
  • Its last three reported values are $29.1 million in Q3 2025, $23.9 million for Q2 2025, and $61.5 million during Q1 2025.